Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 54
Filter
1.
BMC Geriatr ; 23(1): 649, 2023 10 11.
Article in English | MEDLINE | ID: mdl-37821833

ABSTRACT

During the COVID-19 pandemic and compared to other population groups, older people were at a heightened risk of developing lethal disease symptoms. Thus, many countries put in place protective measures to protect this "at-risk" population, especially in nursing homes, to limit the number of infections. These measures consisted mostly in the absence of social gatherings, the impossibility for relatives to enter the nursing homes, limitations in group activities, and the ban of group-eating. Although these measures were helpful to mitigate the spread of the disease, they also induced long periods of social isolation for the residents of nursing homes. This could have impacted the wellbeing and quality of life of residents and their relatives, with a possible impact on the overall health of residents. We designed this rapid review to investigate the literature on the impact of COVID-19 protective measures in nursing homes on the quality of life, wellbeing and physical health of residents and their relatives. Our results showed that most of the articles included in the review, either using qualitative or quantitative methods, evidenced a detrimental impact of protective measures on resident's and their relatives' wellbeing. We argue that, in the event of a new pandemic similar to the COVID-19, protective measures should also take into account their psychological impact, and not only their physical impact.


Subject(s)
COVID-19 , Humans , Aged , COVID-19/epidemiology , COVID-19/prevention & control , Quality of Life/psychology , Pandemics/prevention & control , Nursing Homes , Social Isolation
2.
NPJ Regen Med ; 7(1): 35, 2022 Jun 30.
Article in English | MEDLINE | ID: mdl-35773262

ABSTRACT

While the axolotl's ability to completely regenerate amputated limbs is well known and studied, the mechanism of axolotl bone fracture healing remains poorly understood. One reason might be the lack of a standardized fracture fixation in axolotl. We present a surgical technique to stabilize the osteotomized axolotl femur with a fixator plate and compare it to a non-stabilized osteotomy and to limb amputation. The healing outcome was evaluated 3 weeks, 3, 6 and 9 months post-surgery by microcomputer tomography, histology and immunohistochemistry. Plate-fixated femurs regained bone integrity more efficiently in comparison to the non-fixated osteotomized bone, where larger callus formed, possibly to compensate for the bone fragment misalignment. The healing of a non-critical osteotomy in axolotl was incomplete after 9 months, while amputated limbs efficiently restored bone length and structure. In axolotl amputated limbs, plate-fixated and non-fixated fractures, we observed accumulation of PCNA+ proliferating cells at 3 weeks post-injury similar to mouse. Additionally, as in mouse, SOX9-expressing cells appeared in the early phase of fracture healing and amputated limb regeneration in axolotl, preceding cartilage formation. This implicates endochondral ossification to be the probable mechanism of bone healing in axolotls. Altogether, the surgery with a standardized fixation technique demonstrated here allows for controlled axolotl bone healing experiments, facilitating their comparison to mammals (mice).

4.
Langenbecks Arch Surg ; 404(6): 693-701, 2019 Sep.
Article in English | MEDLINE | ID: mdl-31243574

ABSTRACT

OBJECTIVE: Nausea and vomiting are common side effects following thyroid and parathyroid surgery. In a prospective controlled randomized trial, postoperative nausea and vomiting (PONV) and the number of episodes of vomiting were defined as two primary endpoints. We analysed whether the placement of drains after thyroid or parathyroid surgery enhances PONV and/or influences vomiting. PATIENTS AND METHODS: From November 2007 to January 2012, 136 consecutive patients were included for thyroid or parathyroid surgery and were randomly assigned to group A (drain, n = 69) or group B (no drain, n = 67). PONV was assessed with visual analogue scale (VAS; range 0 to 10) measurements. Furthermore, episodes of vomiting as well as analgetic and antiemetic therapies were recorded. Difference in neck circumference was compared pre- and postoperatively. RESULTS: Patients' characteristics did not differ between group A and B. Postoperative VAS values for pain were 2.4 ± 0.3 (group A) and 2.6 ± 0.2 (group B) (p = 0.62), and for nausea 1.4 ± 0.2 (group A) and 1.1 ± 0.2 (group B) (p = 0.57). The relative occurrences of episodes for postoperative vomiting were equal in both groups 0.3 ± 0.1 (p = 1.0). Antiemetic drugs were administered 37 times (group A) and 18 times (group B) (p = 0.099). The total number of treatments of patients with antiemetic drugs was 23 (33.3%) in group A vs. 13 (19.4%) in group B (p = 0.081). The neck circumference postoperatively was significantly larger in group B (p = 0.0025). CONCLUSIONS: Drains after surgery do not enhance postoperative pain, nausea and vomiting. The placement of drains in thyroid surgery is recommended to avoid relevant fluid collection. Drains however may influence the amount of antiemetic drug requirements. TRIAL REGISTRATION: CLINICALTRIALS. GOV IDENTIFIER: NCT01679418.


Subject(s)
Drainage/methods , Pain, Postoperative/prevention & control , Parathyroidectomy , Postoperative Nausea and Vomiting/prevention & control , Thyroidectomy , Adult , Aged , Aged, 80 and over , Analgesics/therapeutic use , Antiemetics/therapeutic use , Female , Humans , Male , Middle Aged , Pain Measurement , Prospective Studies , Switzerland
5.
Transpl Infect Dis ; 17(5): 751-5, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26432076

ABSTRACT

Multidrug-resistant (MDR) cytomegalovirus (CMV) emerged after transient responses to ganciclovir, foscarnet, and cidofovir in a CMV-seropositive recipient who underwent allogeneic hematopoietic stem cell transplantation from a CMV-seronegative donor. Experimental treatments using leflunomide and artesunate failed. Re-transplantation from a CMV-seropositive donor supported by adoptive transfer of pp65-specific T cells and maribavir was followed by lasting suppression. This case illustrates that successful MDR CMV therapy may require individualized multidisciplinary approaches.


Subject(s)
Cytomegalovirus Infections/therapy , Drug Resistance, Multiple, Viral , Hematopoietic Stem Cell Transplantation , Immunocompromised Host , Adoptive Transfer , Antiviral Agents/therapeutic use , Combined Modality Therapy , Cytomegalovirus Infections/immunology , Drug Therapy, Combination , Humans , Male , Middle Aged
6.
Bone Marrow Transplant ; 50(11): 1453-8, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26301968

ABSTRACT

The nestin(+) perivascular bone marrow (BM) stem cell niche (N(+)SCN) may be involved in GvHD. To investigate whether acute GvHD (aGvHD) reduces the number of N(+)SCN, we examined patients with AML who had undergone allogeneic hematopoietic stem cell transplantation. In the test cohort (n=8), the number of N(+)SCN per mm(2) in BM biopsies was significantly reduced in aGvHD patients at the time of aGvHD compared with patients who did not have aGvHD (1.2±0.78 versus 2.6±0.93, P=0.04). In the validation cohort (n=40), the number of N(+)SCN was reduced (1.9±0.99 versus 2.6±0.90 N(+)SCN/mm(2), P=0.05) in aGvHD patients. Receiver operating curves suggested that the cutoff score that best discriminated between patients with and without aGvHD was 2.29 N(+)SCN/mm(2). Applying this cutoff score, 9/11 patients with clinically relevant aGvHD (⩾grade 2) and 13/20 with any type of GvHD had decreased N(+)SCN numbers compared with only 10/29 patients without clinically relevant aGvHD (P=0.007) and 6/20 patients without any type of GvHD (P=0.028). In patients tracked over time, N(+)SCN density returned to normal after aGvHD resolved or remained stable in patients who did not have aGvHD. Our results show a decrease in the number of N(+)SCN in aGvHD.


Subject(s)
Bone Marrow/pathology , Graft vs Host Disease/pathology , Hematopoietic Stem Cell Transplantation/adverse effects , Nestin/analysis , Stem Cell Niche , Acute Disease , Adult , Aged , Allografts , Antigens, CD34/analysis , Area Under Curve , Biomarkers , Bone Marrow/blood supply , Bone Marrow/physiology , Cell Differentiation , Cohort Studies , Female , Forkhead Transcription Factors/analysis , Graft vs Host Disease/etiology , Hematologic Neoplasms/therapy , Humans , Male , Microvessels/pathology , Middle Aged , Neovascularization, Pathologic/etiology , Neovascularization, Pathologic/pathology , Procollagen/analysis , ROC Curve , Regeneration , Transplantation Conditioning/adverse effects
7.
J Sound Vib ; 344: 101-113, 2015 May 26.
Article in English | MEDLINE | ID: mdl-26023245

ABSTRACT

This paper provides new formulations to derive the impulse response matrix, which is then used in the problem of load identification with application to wind induced vibration. The applied loads are inversely identified based on the measured structural responses by solving the associated discrete ill-posed problem. To this end - based on an existing parametric structural model - the impulse response functions of acceleration, velocity and displacement have been computed. Time discretization of convolution integral has been implemented according to an existing and a newly proposed procedure, which differ in the numerical integration methods. The former was evaluated based on a constant rectangular approximation of the sampled data and impulse response function in a number of steps corresponding to the sampling rate, while the latter interpolates the sampled data in an arbitrary number of sub-steps and then integrates over the sub-steps and steps. The identification procedure was implemented for a simulation example as well as an experimental laboratory case. The ill-conditioning of the impulse response matrix made it necessary to use Tikhonov regularization to recover the applied force from noise polluted measured response. The optimal regularization parameter has been obtained by L-curve and GCV method. The results of simulation represent good agreement between identified and measured force. In the experiments the identification results based on the measured displacement as well as acceleration are provided. Further it is shown that the accuracy of experimentally identified load depends on the sensitivity of measurement instruments over the different frequency ranges.

8.
Brain Behav Immun ; 33: 153-63, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23880236

ABSTRACT

The prevalence of neurodevelopmental disorders such as autism is increasing, however the etiology of these disorders is unclear and thought to involve a combination of genetic, environmental and immune factors. A recent epidemiological study found that gestational viral exposure during the first trimester increases risk of autism in offspring by twofold. In mice gestational viral exposures alter behavior of offspring, but the biological mechanisms which underpin these behavioral changes are unclear. We hypothesized that gestational viral exposure induces changes in affiliative hormones, brainstem autonomic nuclei and neurotransmitters which are associated with behavioral alterations in offspring. To address this hypothesis, we exposed pregnant mice to influenza A virus (H3N2) on gestational day 9 and determined behavioral, hormonal and brainstem changes in male and female offspring. We found that gestational flu exposure induced dose-dependent alterations in social and aggressive behaviors (p≤0.05) in male and female offspring and increases in locomotor behaviors particularly in male offspring (p≤0.05). We found that flu exposure was also associated with reductions in oxytocin and serotonin (p≤0.05) levels in male and female offspring and sex-specific changes in dopamine metabolism. In addition we found changes in catecholaminergic and microglia density in brainstem tissues of male flu exposed offspring only (p≤0.05). This study demonstrates that gestational viral exposure induces behavioral changes in mice, which are associated with alterations in affiliative hormones. In addition we found sex-specific changes in locomotor behavior, which may be associated with sex-specific alterations in dopamine metabolism and brainstem inflammation. Further investigations into maternal immune responses are necessary to unravel the molecular mechanisms which underpin abnormal hormonal, immune and behavioral responses in offspring after gestational viral exposure.


Subject(s)
Autistic Disorder/etiology , Brain Stem/immunology , Brain Stem/pathology , Influenza A Virus, H3N2 Subtype , Orthomyxoviridae Infections/immunology , Orthomyxoviridae Infections/pathology , Oxytocin/blood , Testosterone/blood , Animals , Autistic Disorder/immunology , Autistic Disorder/pathology , Blood Glucose/analysis , Body Weight/immunology , Brain Stem/virology , Chromatography, High Pressure Liquid , Female , Inflammation/immunology , Inflammation/pathology , Inflammation/virology , Male , Maternal Exposure/adverse effects , Mice , Mice, Inbred BALB C , Motor Activity/immunology , Orthomyxoviridae Infections/complications , Pilot Projects , Pregnancy , Random Allocation , Stereotyped Behavior
9.
Bone Marrow Transplant ; 48(5): 715-21, 2013 May.
Article in English | MEDLINE | ID: mdl-23085826

ABSTRACT

There is increasing evidence suggesting that both angiogenesis and endothelial injury are involved in GVHD. To study the dynamics of angiogenesis, we examined 26 patients with AML who had undergone allogeneic haematopoietic SCT. All were in CR and had either acute GVHD (aGVHD) or chronic GVHD (cGVHD). We performed immunohistochemical studies of BM microvessel density (MVD) using Abs against vascular-endothelial (VE)-cadherin, CD34 and CD105, and expression of vascular endothelial growth factor (VEGF) and its receptors VEGFR-1 and VEGFR-2. At the time of diagnosis, the MVD in AML patients was higher than that in the normal controls, and the MVD decreased after induction chemotherapy. Patients with aGVHD had a significantly higher MVD than patients without aGVHD. Conversely, patients with cGVHD did not have a significantly different MVD. In previous aGVHD, we also found more VEGF+ megakaryocytes. XY FISH in sex-mismatched patients showed that the BM blood vessels consisted mainly of recipient endothelial cells. Taken together, these results suggest that new vessel formation and the VEGF/VEGFR system are involved in aGVHD.


Subject(s)
Bone Marrow/metabolism , Graft vs Host Disease/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Leukemia, Myeloid, Acute/metabolism , Leukemia, Myeloid, Acute/surgery , Receptors, Vascular Endothelial Growth Factor/biosynthesis , Vascular Endothelial Growth Factor A/biosynthesis , Adult , Aged , Female , Graft vs Host Disease/immunology , Graft vs Host Disease/metabolism , Hematopoietic Stem Cell Transplantation/methods , Humans , Immunohistochemistry , Leukemia, Myeloid, Acute/pathology , Male , Middle Aged , Neovascularization, Pathologic/metabolism , Receptors, Vascular Endothelial Growth Factor/metabolism , Vascular Endothelial Growth Factor A/metabolism , Young Adult
10.
Infection ; 40(6): 677-84, 2012 Dec.
Article in English | MEDLINE | ID: mdl-22802096

ABSTRACT

BACKGROUND: The clinical characteristics of human metapneumovirus (hMPV)-associated lower respiratory tract infection (LRTI) after allogeneic hematopoietic stem cell transplantation (HSCT) is not well described. We describe the clinical course in eight HSCT recipients suffering from hMPV infection. METHODS: We prospectively included all patients with hMPV-associated LRTI after allogeneic HSCT during a period of 1 year. hMPV was diagnosed by multiplex polymerase chain reaction (PCR) from bronchoalveolar lavage (BAL). RESULTS: Eight patients with hMPV-associated LRTI were identified from 93 BAL samples. Three of the eight patients had co-infections with other pathogens. The median age of the patients was 45 years [interquartile range (IQR) 36.8-53.5], the median time posttransplant was 473 days (IQR 251-1,165), 5/8 patients had chronic graft-versus-host disease (cGvHD), and 6/8 patients received immunosuppression. Chest computed tomography (CT) scanning showed a ground-glass pattern in 7/8 patients. Seven of eight patients required hospitalization due to severe symptoms and hypoxemia. All were treated with intravenous immunoglobulin (IVIG), which was combined with oral ribavirin in six patients. The mortality rate was 12.5 % (1/8). CONCLUSIONS: hMPV-associated LRTI in allogeneic HSCT recipients are not uncommon and present with unspecific respiratory symptoms, ground-glass pattern in CT scanning, and co-infection.


Subject(s)
Hematopoietic Stem Cell Transplantation/adverse effects , Metapneumovirus/isolation & purification , Paramyxoviridae Infections/etiology , Respiratory Tract Infections/etiology , Adult , Antiviral Agents/therapeutic use , Drug Therapy, Combination , Female , Humans , Immunocompromised Host , Immunoglobulins, Intravenous/therapeutic use , Male , Middle Aged , Paramyxoviridae Infections/diagnosis , Paramyxoviridae Infections/drug therapy , Respiratory Tract Infections/diagnosis , Respiratory Tract Infections/drug therapy , Reverse Transcriptase Polymerase Chain Reaction , Ribavirin/therapeutic use , Tomography, X-Ray Computed , Transplantation, Homologous
11.
Bone Marrow Transplant ; 46(5): 636-40, 2011 May.
Article in English | MEDLINE | ID: mdl-20697364

ABSTRACT

Treatment strategies for relapsed/refractory AML are limited and disappointing. Recently, high-dose melphalan (HDM) chemotherapy and autologous hematopoietic SCT (HSCT) has been proposed for AML re-induction. We investigated the impact of HDM remission induction in highly advanced relapsed/refractory AML patients planned for allogeneic HSCT. A total of 23 patients with relapsed/refractory AML were prospectively scheduled for HDM with or without stem cell support followed by myeloablative allogeneic HSCT. Patients included nine individuals with a history of previous HSCT (seven allogeneic, two autologous). A total of 18 patients (78%) achieved a leukemia-free state and an additional four had substantial reduction of the initial leukemia burden warranting treatment continuation. There were no differences between patients with or without immediate stem cell support regarding mucositis or other organ toxicity. A total of 20 patients proceeded to myeloablative allogeneic HSCT. Outcome of allogeneic HSCT was poor: 11 patients (55%) relapsed, 7 patients (35%) died from TRM and only 2 patients (10%) were alive at the last follow-up. Our study shows that HDM is effective in inducing a leukemia-free state in patients with highly advanced relapsed/refractory AML. Leukemia burden reduction with HDM, however, did not translate into improved OS.


Subject(s)
Leukemia, Myeloid, Acute/therapy , Melphalan/administration & dosage , Transplantation Conditioning/methods , Adult , Aged , Female , Hematopoietic Stem Cell Transplantation/adverse effects , Hematopoietic Stem Cells/drug effects , Humans , Male , Melphalan/adverse effects , Middle Aged , Myeloablative Agonists/therapeutic use , Recurrence , Remission Induction/methods , Transplantation, Autologous , Treatment Outcome
12.
Bone Marrow Transplant ; 46(5): 740-6, 2011 May.
Article in English | MEDLINE | ID: mdl-20697371

ABSTRACT

Hematopoietic SCT (HSCT) after non-myeloablative conditioning is associated with reduced TRM, and increased risk of graft rejection. Although preclinical data have shown the importance of post transplant immunosuppression in achieving engraftment, little is known about the role of CSA in the clinical setting of non-myeloablative transplantation. In a retrospective analysis of patients treated with allogeneic HSCT after fludarabine and 2 Gy TBI, 15 of 77 evaluable patients (20%) experienced primary (n=2) or secondary graft rejection at a median of 66 days post transplant. Mean day 1-28 CSA trough levels were inversely associated with day 28 chimerism (median 99, 85 and 70% for mean CSA <300, 300-600 and >600 ng/mL, respectively; P=0.003). A similar association was observed for the cumulative incidence of graft rejection, which occurred in 8% (<300 ng/mL), 26% (300-600 ng/mL) and 50% (>600 ng/mL, P=0.005) of patients. The detrimental effect of high CSA levels on engraftment was confirmed in multivariable models and was found to operate comparably in sibling and unrelated donor transplants. Impairment of donor T-cell function by high serum levels of CSA might account for this finding, which should be verified in a larger patient group to better understand the role of CSA in non-myeloablative transplantation.


Subject(s)
Cyclosporine/adverse effects , Graft Rejection/etiology , Hematopoietic Stem Cell Transplantation/adverse effects , Transplantation Conditioning/adverse effects , Vidarabine/analogs & derivatives , Adult , Aged , Cyclosporine/administration & dosage , Cyclosporine/blood , Female , Humans , Immunosuppression Therapy/methods , Male , Middle Aged , Retrospective Studies , Transplantation Chimera , Transplantation Conditioning/methods , Vidarabine/therapeutic use , Whole-Body Irradiation
13.
Bone Marrow Transplant ; 46(3): 344-9, 2011 Mar.
Article in English | MEDLINE | ID: mdl-20548339

ABSTRACT

BU-CY is the established non-TBI-based myeloablative conditioning regimen for allogeneic hematopoietic SCT. However, liver toxicity and hepatic veno-occlusive disease (VOD) are frequent life-threatening complications. Pharmacological considerations suggest that BU can trigger toxicity of subsequent CY. Recent animal data confirmed this hypothesis. Less liver toxicity and better outcomes were observed when mice were treated with the reversed order of CY and BU. We analyzed in this study liver toxicity and outcome in patients receiving BU-CY (16 patients) or CY-BU (59 patients). Liver function differed significantly with higher levels of liver function tests between day +10 and +30, and a higher cumulative incidence of VOD in the BU-CY cohort (2/16 (12.5%) vs 0/59 (0%), P=0.006). TRM was significantly higher in patients receiving BU-CY (cumulative incidence BU-CY 45%, CY-BU 17%, P=0.02), without yet translating into a significant survival difference (incidence for survival: BU-CY 38%, CY-BU 63%; hazard ratio 1.19 for BU-CY, 95% confidence interval 0.29-4.82, P=0.80). Rates of engraftment and relapse were not different. These data support the concepts derived from animal models in favor of CY-BU compared with traditional BU-CY and form the basis for prospective controlled comparisons.


Subject(s)
Busulfan/adverse effects , Chemical and Drug Induced Liver Injury/etiology , Cyclophosphamide/adverse effects , Hematopoietic Stem Cell Transplantation/adverse effects , Hepatic Veno-Occlusive Disease/chemically induced , Liver/drug effects , Transplantation Conditioning/adverse effects , Adolescent , Adult , Aged , Busulfan/administration & dosage , Chemical and Drug Induced Liver Injury/immunology , Chemical and Drug Induced Liver Injury/pathology , Cohort Studies , Cyclophosphamide/administration & dosage , Drug Administration Schedule , Female , Graft vs Host Disease/immunology , Graft vs Host Disease/prevention & control , Hepatic Veno-Occlusive Disease/immunology , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/adverse effects , Liver/pathology , Male , Middle Aged , Retrospective Studies , Transplantation Conditioning/methods , Treatment Outcome , Young Adult
14.
Bone Marrow Transplant ; 39(6): 335-40, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17342158

ABSTRACT

Patients with refractory/relapsing lymphoma are rarely cured by chemotherapy. High-dose chemotherapy (HDC) for tumor debulking followed by reduced-intensity conditioning (RIC) hematopoietic stem-cell transplantation (HSCT) has been advocated as a concept. We previously treated 10 patients (group A) with BEAM chemotherapy followed by delayed RIC HSCT at day 28. We now report on the subsequent 11 patients receiving BEAM followed immediately by fludarabine/total body irradiation and allogeneic HSCT (group B), and compare the outcome to group A patients. Non-hematological toxicity before engraftment was comparable, only gut toxicity was higher in group B. Days in aplasia, days on antibiotics and length of hospital stay were significantly longer in group A. Cumulative incidence of acute (GvHD) >or=grade II and incidence of chronic GvHD were lower in group B. At last follow-up, seven patients in group A were alive, with six of them in complete remission. In group B, nine patients were alive, seven of them in complete remission. No significant difference in estimated 3-year overall survival was seen. These data challenge the initial concept of debulking first and delaying allogeneic RIC HSCT. Allogeneic HSCT with standard BEAM conditioning is a valid alternative for patients with resistant/relapsed lymphoma, which might be considered earlier in the disease course.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hematopoietic Stem Cell Transplantation/methods , Lymphoma/drug therapy , Transplantation Conditioning/methods , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carmustine/administration & dosage , Cytarabine/administration & dosage , Etoposide/administration & dosage , Female , Graft vs Host Disease , Graft vs Tumor Effect , Humans , Kaplan-Meier Estimate , Male , Melphalan/administration & dosage , Remission Induction/methods , Transplantation, Homologous
16.
Bone Marrow Transplant ; 33(10): 1011-4, 2004 May.
Article in English | MEDLINE | ID: mdl-15064693

ABSTRACT

In patients with refractory lymphoma, we tested the hypothesis that high-dose chemotherapy (BEAM) without stem cell support followed by a reduced intensity (RIC) allogeneic transplant with fludarabine and 2 Gy TBI 28 days later results in tumor debulking and establishment of a graft vs lymphoma effect, with acceptable toxicity. In a pilot protocol we treated 10 patients, 22-62 (median 47) years of age with high-risk or refractory Hodgkin's or non-Hodgkin's lymphoma. Donors were HLA identical siblings (eight) or unrelated volunteers. None died during the neutropenic phase after BEAM which lasted up to the RIC HSCT. The duration of neutropenia was 31-43 (median 36) days. All patients engrafted and nine achieved CR. All developed acute GvHD (median grade III) and all patients at risk developed chronic GvHD. Three patients died of GvHD. One relapsed and six patients are in continuous CR 10-32 (median 15) months after HSCT. This approach appears feasible and results in a high response rate. Neutropenia duration is of concern. It remains to be tested whether separation of debulking chemotherapy and induction of allogeneic effects confers an advantage.


Subject(s)
Graft vs Tumor Effect , Lymphoma/therapy , Vidarabine/analogs & derivatives , Adolescent , Adult , Antineoplastic Agents/pharmacology , Disease Progression , Drug Therapy , Female , Hematopoietic Stem Cell Transplantation , Hodgkin Disease/therapy , Humans , Lymphoma, Non-Hodgkin/therapy , Male , Middle Aged , Neutropenia , Prognosis , Prospective Studies , Recurrence , Remission Induction , Risk , Time Factors , Transplantation Conditioning , Transplantation, Homologous , Treatment Outcome , Vidarabine/pharmacology
17.
Eur Heart J ; 24(6): 541-51, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12643887

ABSTRACT

AIMS: To investigate the clinical and angiographic outcome of patients with mild coronary lesions treated with balloon angioplasty or coronary stenting (coronary plaque sealing, i.e. dilatation of angiographically non-significant lesions) compared to moderate and severe stenoses. METHODS AND RESULTS: Patients with chronic stable angina and a single de novo lesion in a native coronary vessel scheduled to undergo percutaneous coronary intervention (PCI) were selected from 14 different studies. Off-line analysis of angiographic outcomes was assessed in all patients using identical and standardised methods of data acquisition, analysis and definitions. Clinical endpoints were adjudicated by independent clinical events committees. All quantitative coronary angiographic (QCA) analyses were performed in the same core laboratory. Stenosis severity prior to PCI was categorised into three groups: <50% diameter stenosis (DS), 50-99%DS and >99%DS pre. A total of 3812 patients were included in this study; 1484 patients (39%) were successfully treated with balloon angioplasty (BA) only and stented angioplasty was performed in 2328 patients (61%).One-year mortality and rate of non-fatal myocardial infarction (MI) (Kaplan-Meier) did not differ between BA and stented angioplasty for any of the stenosis severity categories. Following BA, the combined event rate (death and non-fatal MI) was 4.8, 4.6 and 0% in the <50, 50-99 and >99%DS categories, respectively. Following stented angioplasty, the combined event rate was 3.1, 4.4 and 4.8% in the same categories. The need for repeat revascularisation corrected for stenosis severity in the Cox proportional-hazards regression model was reduced by 20% after stented angioplasty (hazard ratio (HR) 0.80, 95%CI 0.69-0.93). CONCLUSION: The concept of plaque sealing is appealing from the theoretical point of view. However, with current technology, plaque sealing cannot prevent death and future non-fatal MIs in the long-term because 1-year event rates after PCI of non-significant stenoses remain unacceptably elevated when compared with the estimated 1-year probability of a non-fatal MI in lesions with a <50%DS. Moreover, major adverse cardiac events at 1-year after PCI are not directly related to the degree of pre-procedural stenosis severity.


Subject(s)
Catheterization/methods , Coronary Stenosis/therapy , Stents , Angina Pectoris/etiology , Coronary Angiography/methods , Coronary Restenosis/diagnostic imaging , Coronary Restenosis/prevention & control , Coronary Stenosis/diagnostic imaging , Death, Sudden, Cardiac , Disease-Free Survival , Female , Humans , Male , Middle Aged , Myocardial Infarction/diagnostic imaging , Myocardial Infarction/etiology , Postoperative Care , Randomized Controlled Trials as Topic , Treatment Outcome
18.
Am J Pathol ; 159(6): 2249-56, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11733374

ABSTRACT

Advances in genomics and proteomics are dramatically increasing the need to evaluate large numbers of molecular targets for their diagnostic, predictive or prognostic value in clinical oncology. Conventional molecular pathology techniques are often tedious, time-consuming, and require a lot of tissue, thereby limiting both the number of tissues and the number of targets that can be evaluated. Here, we demonstrate the power of our recently described tissue microarray (TMA) technology in analyzing prognostic markers in a series of 553 breast carcinomas. Four independent TMAs were constructed by acquiring 0.6 mm biopsies from one central and from three peripheral regions of each of the formalin-fixed paraffin embedded tumors. Immunostaining of TMA sections and conventional "large" sections were performed for two well- established prognostic markers, estrogen receptor (ER) and progesterone receptor (PR), as well as for p53, another frequently examined protein for which the data on prognostic utility in breast cancer are less unequivocal. Compared with conventional large section analysis, a single sample from each tumor identified about 95% of the information for ER, 75 to 81% for PR, and 70 to 74% for p53. However, all 12 TMA analyses (three antibodies on four different arrays) yielded as significant or more significant associations with tumor-specific survival than large section analyses (p < 0.0015 for each of the 12 comparisons). A single sample from each tumor was sufficient to identify associations between molecular alterations and clinical outcome. It is concluded that, contrary to expectations, tissue heterogeneity did not negatively influence the predictive power of the TMA results. TMA technology will be of substantial value in rapidly translating genomic and proteomics information to clinical applications.


Subject(s)
Biomarkers/analysis , Breast Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Breast Neoplasms/metabolism , Female , Humans , Immunohistochemistry , Middle Aged , Prognosis , Receptors, Estrogen/analysis , Receptors, Progesterone/analysis , Survival Analysis , Tumor Suppressor Protein p53/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...